A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

Cannot have received: systemic or localised anti-cancer treatment

Prior treatment with any systemic or localised anti-cancer treatment for the localised prostate cancer

Cannot have received: chemotherapy

Exception: Previously localised surgically treated malignancy is acceptable, if no evidence of recurrence.

History of prior malignancy, treated with chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, or other anticancer agent within 3 years of screening

Cannot have received: biological therapy

Exception: Previously localised surgically treated malignancy is acceptable, if no evidence of recurrence.

History of prior malignancy, treated with chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, or other anticancer agent within 3 years of screening

Cannot have received: radiation therapy

Exception: Previously localised surgically treated malignancy is acceptable, if no evidence of recurrence.

History of prior malignancy, treated with chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, or other anticancer agent within 3 years of screening

Cannot have received: androgen

Exception: Previously localised surgically treated malignancy is acceptable, if no evidence of recurrence.

History of prior malignancy, treated with chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, or other anticancer agent within 3 years of screening

Cannot have received: thalidomide

Exception: Previously localised surgically treated malignancy is acceptable, if no evidence of recurrence.

History of prior malignancy, treated with chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, or other anticancer agent within 3 years of screening

Cannot have received: immunotherapy

Exception: Previously localised surgically treated malignancy is acceptable, if no evidence of recurrence.

History of prior malignancy, treated with chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, or other anticancer agent within 3 years of screening

Cannot have received: anticancer agent

Exception: Previously localised surgically treated malignancy is acceptable, if no evidence of recurrence.

History of prior malignancy, treated with chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, or other anticancer agent within 3 years of screening